HP Launches Cloud based Global Authentication Service in India to Fight Counterfeit Drugs
HP has launched a new Cloud based Global Authentication system for monitoring the movement of Drugs, The first country to reap the benefits is going to be India. Hp plans a global systematic launch in the coming months. India was primarily selected due to the phenomenal growth in the country’s pharmaceutical industry, which also is seeing the development of a parallel counterfeit drug market. The service, which runs on scalable, cloud-based technology, also can be deployed in other industry sectors, offered in any geographical region and incorporated into an existing drug production system.
The HP Global Authentication Service allows pharmaceutical companies to monitor the movement of products through their global supply chains with a much higher degree of accuracy. This helps protect consumers against dangerous or ineffective drugs and enables pharmaceutical companies to protect their revenue and intellectual property from the growing black market.
HP technology is not only providing commercial benefits to our clients, but also is helping to save lives. The success to date with mPedigree and subsequent commercialization of our Global Authentication Service highlights how valuable social innovation initiatives can be in helping bring innovative service offerings to the market.”
– Prith Banerjee, senior vice president, Research, and director, HP Labs
This is an excellent initiative from HP. Each year over 240,000 lives are lost in India due to the use of fake/counterfeit drugs, this technology will lower the chances
[toggle title_open=”Collapse” title_closed=”Read The Press Release” hide=”yes” border=”yes” style=”default” excerpt_length=”0″ read_more_text=”Read More” read_less_text=”Read Less” include_excerpt_html=”no”]
HP Launches Global Authentication Service to Fight Counterfeit Drugs. Cloud based service developed at HP Labs, will be rolling out in India first
HP has launched its Global Authentication Service, a cloud-based track-and-trace solution based on technology that has been used to fight the global problem of counterfeit and stolen drugs, estimated to claim 700,000 lives every year(1) and representing an illegal $75 billion global industry.(2)
The HP Global Authentication Service allows pharmaceutical companies to monitor the movement of products through their global supply chains with a much higher degree of accuracy. This helps protect consumers against dangerous or ineffective drugs and enables pharmaceutical companies to protect their revenue and intellectual property from the growing black market.
The service is initially being rolled out in India due to the phenomenal growth in the country’s pharmaceutical industry, which also is seeing the development of a parallel counterfeit drug market. The service, which runs on scalable, cloud-based technology, also can be deployed in other industry sectors, offered in any geographical region and incorporated into an existing drug production system.
The service’s underlying technology engine was originally developed by HP Labs – the company’s central research arm – and the HP Software Professional Services Cloud Services Innovation Center to monitor goods in HP’s supply chain. It was later adapted for use in product recalls in the food industry.
The solution was most recently adapted and deployed in collaboration with the African nonprofit social enterprise mPedigree to track, trace and authenticate a range of life-saving medications in Nigeria and Ghana, with a rollout planned for more countries later this year.
The HP Global Authentication Service works in conjunction with HP’s global printing partners who are able to print quality labels in high volumes very efficiently even when required in some of the world’s most remote locations.
“HP technology is not only providing commercial benefits to our clients, but also is helping to save lives,” said Prith Banerjee, senior vice president, Research, and director, HP Labs. “The success to date with mPedigree and subsequent commercialization of our Global Authentication Service highlights how valuable social innovation initiatives can be in helping bring innovative service offerings to the market.”
Background
As of 2009, India’s pharmaceuticals industry was estimated at $21.04 billion.(3) As this industry grows, so does the associated risk of a counterfeit market. While India is a leading manufacturer and exporter of high-quality generic and patent drugs, the Organization for Economic Co-operation and Development ranked the country as the largest source of counterfeit medicine, with 75 percent of counterfeit drugs worldwide having some origins in India.
– Counterfeit drugs often contain the wrong quantity of active pharmaceutical ingredients, which can result in illness or death.
– Counterfeit drugs account for approximately 10 percent of the global drug market.(3)
– The use of counterfeit drugs is estimated to finance a $75 billion global counterfeit pharmaceutical industry.(2)
– The World Health Organization estimates that counterfeit drugs constitute 25 percent of the drug market in developing countries.(4)
– Across Africa, 30 percent of malaria medications are estimated to be counterfeit.(1)
Supporting resources
More information about HP’s work in social innovation for healthcare is available at HP’s Office of Global Social Innovation website.
Additional information regarding the work of mPedigree is available in an interview with founder Bright Simons and at Data Central, the HP corporate blog.
Information about HP’s award-winning work with the Clinton Health Access Initiative (CHAI) and social enterprise mPedigree also is available at Data Central.
(1) “Keeping It Real: Protecting the world’s poor from fake drugs,” International Policy Network, May 2009.
(2) “21st Century Health Care Terrorism: The Perils of International Drug Counterfeiting,” Center for Medicine in the Public Interest, September 2005.
(3) “Background on Indian Pharmaceutical industry,” Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, July 2010.
(4) “Standard and Counterfeit Medicines,” World Health Organization, November 2003.
Notes to Editor
About HP
HP creates new possibilities for technology to have a meaningful impact on people, businesses, governments and society. The world’s largest technology company, HP brings together a portfolio that spans printing, personal computing, software, services and IT infrastructure at the convergence of the cloud and connectivity, creating seamless, secure, context-aware experiences for a connected world. More information about HP (NYSE: HPQ) is available at http://www.hp.com.
This news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of HP and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to statements of the plans, strategies and objectives of management for future operations; any statements concerning expected development, performance or market share relating to products and services; any statements regarding anticipated operational and financial results; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. Risks, uncertainties and assumptions include macroeconomic and geopolitical trends and events; the competitive pressures faced by HP’s businesses; the development and transition of new products and services (and the enhancement of existing products and services) to meet customer needs and respond to emerging technological trends; the execution and performance of contracts by HP and its customers, suppliers and partners; the achievement of expected operational and financial results; and other risks that are described in HP’s Quarterly Report on Form 10-Q for the fiscal quarter ended April 30, 2011 and HP’s other filings with the Securities and Exchange Commission, including but not limited to HP’s Annual Report on Form 10-K for the fiscal year ended October 31, 2010. HP assumes no obligation and does not intend to update these forward-looking statements.
© 2011 Hewlett-Packard Development Company, L.P. The information contained herein is subject to change without notice. The only warranties for HP products and services are set forth in the express warranty statements accompanying such products and services. Nothing herein should be construed as constituting an additional warranty. HP shall not be liable for technical or editorial errors or omissions contained herein.
[/toggle]
